ReviewAnaerobe2026
The impact of fecal microbiota transplantation on host immunity and epithelial restoration following Clostridioides difficile infection.
Review in Anaerobe, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Fecal microbiota transplantation (FMT) has emerged as an effective therapy for the prevention of recurrent Clostridioides difficile infection (rCDI). Despite this therapeutic success, questions remain about safety and standardization of protocols, leading to calls for more defined biotherapeutics. While FMT-mediated protection is associated with restoration of the intestinal microbiota and metabolome, our understanding of its impact on host immune responses and restoration of colonic homeostasis remains incomplete. In this review, we focus on our current knowledge regarding the effects of FMT on host responses, including immune responses, colonic barrier restoration, and host metabolism. FMT is associated with restoration of immune signaling, which is depleted following antibiotic therapy. Restoration is associated with a shift towards type 2 and regulatory immune responses that limit intestinal inflammation and promote repair. FMT also modifies non-immune cells, promoting enhanced barrier integrity and significantly modifying host metabolism within the gut. FMT studies utilize a variety of experimental protocols and FMT formulations, and more mechanistic studies are required to understand how this variation impacts microbiota and host-directed changes. Better understanding of the immune and metabolic changes associated with protection against rCDI will allow for the design of more targeted therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.